Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
| ▸ | GALR3 | O60755 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172467 | 0.98 | CYP1A2 (0.40) | CYP1A2CYP2C9MITFALPLPOLB | |
| Potassium Ion SCHEMBL6131368 | 0.95 | CYP1A2 (0.39) | CYP1A2CYP2C9MITFALPLPOLB | |
| SCHEMBL6131347 | 0.95 | CYP1A2 (0.39) | CYP1A2CYP2C9MITFALPLPOLB | |
| Ammonia Solution, Strong SCHEMBL9727420 | 0.95 | CYP1A2 (0.39) | CYP1A2CYP2C9MITFALPLPOLB | |
| Ammonia Solution, Strong SCHEMBL9727425 | 0.80 | CYP1A2 (0.36) | CYP1A2CYP2C9 | |
| SCHEMBL6131370 | 0.80 | CYP1A2 (0.36) | CYP1A2CYP2C9 | |
| SCHEMBL6131346 | 0.80 | CYP1A2 (0.36) | CYP1A2CYP2C9 | |
| SCHEMBL28209261 | 0.80 | CYP1A2 (0.43) | CYP1A2CYP2C9MAPT | |
| SCHEMBL9471612 | 0.80 | CYP1A2 (0.31) | CYP1A2CYP2C9 | |
| SCHEMBL9476367 | 0.80 | CYP1A2 (0.31) | CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881847-B2 | Process for the synthesis and recovery of nitramines | ALLIANT TECHSYSTEMS INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-20040024223-A1 | Process for the synthesis and recovery of nitramines | NORTHROP GRUMMAN SYSTEMS CORPORATION | 2004-02-05 | — | — | US | disclosed |
| US-6603018-B2 | Rockets; propullants | ALLIANT TECHSYSTEMS INC. | 2003-08-05 | — | — | US | disclosed |
| US-20020156291-A1 | Process for the synthesis and recovery of nitramines | ORBITAL ATK, INC. (F/K/A ALLIANT TECHSYSTEMS INC.) | 2002-10-24 | — | — | US | disclosed |
| WO-2002060881-A1 | PROCESS FOR THE SYNTHESIS AND RECOVERY OF NITRAMINES | ALLIANT TECHSYSTEMS INC. (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156291-A1 | Process for the synthesis and recovery of nitramines | NNMT, PNMT, NISCH | CYP1A2 507/4885CYP2C9 777/4885MITF 2245/4885 |
| US-20040024223-A1 | Process for the synthesis and recovery of nitramines | NNMT, NCL, PNMT | CYP1A2 585/4885CYP2C9 854/4885MITF 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.